Clinical trials: Dual Anti-Platelet Therapy
Coronary Artery Disease
Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
The study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus steeply discontinued clopidogrel plus aspirin in preventing clinical MACE events.Our subject is beyond a 12-month period patients…
- Trial name
- EASTS (NCT01233167)
- Testing
- clopidogrel
- Volunteers
- 5,232 people
- Sponsor
- Sir Run Run Shaw Hospital
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
The purpose of this study is to evaluate the effectiveness and safety of abciximab (an anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.
- Trial name
- NCT00269893
- Testing
- Abciximab
- Volunteers
- 2,038 people
- Sponsor
- Centocor, Inc.
Haemostasis, Healthy
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers…
- Trial name
- NCT01561950
- Testing
- eptacog alfa (activated), clopidogrel
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
Dual Anti-platelet Therapy
REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bleeding while on DAPT.
- Trial name
- RE-SCORE (NCT03526614)
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- University of Roma La Sapienza
CLTI Defined as Rutherford Category 4 or 5
Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization
Chronic limb threatening ischemia (CLTI) is defined as ischemic foot pain at rest or non-healing foot wounds that is attributable to severe peripheral arterial disease (PAD).Revascularization is the cornerstone of therapy to…
- Trial name
- DAPTCLTI (NCT07512960)
- Testing
- Clopidogrel 75 mg/day
- Where
- France
- Volunteers
- 614 people
- Sponsor
- Fondation Hôpital Saint-Joseph
G6PD Deficiency, Stroke
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention.
- Trial name
- SAST (NCT04088513)
- Testing
- Aspirin, Clopidogrel
- Where
- 19 sites in China
- Volunteers
- 440 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
The purpose of this study is to compare the efficacy and safety for 12- vs. 1-month of pantoprazole treatment in preventing dual antiplatelet therapy (DAPT)-related upper gastrointestinal mucosal injury after coronary artery…
- Conditions
- Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy, Coronary Artery Bypass
- Trial name
- DACAB-GI-2 (NCT03908593)
- Testing
- Pantoprazole
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Ruijin Hospital
Immune Thrombocytopenia, Treatment
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
To evaluate the efficacy and safety of CM313 in the treatment of immune thrombocytopenia in patients who have failed glucocorticoid therapy.
- Trial name
- NCT06199089
- Testing
- CM313 Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Coronary Syndrome
Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent
Background: The optimal duration of dual antiplatelet therapy in ACS patients treated with DES is still under debate. This is especially true for STEMI patients in the era of new anticoagulants and antiplatelet agents.
- Trial name
- REDUCE (NCT02118870)
- Testing
- Treatment 90 days DAPT, Treatment 360 days DAPT
- Volunteers
- 1,500 people
- Sponsor
- Diagram B.V.
High Bleeding Risk Patients, Cardiology
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events…
- Conditions
- High Bleeding Risk Patients, Cardiology, Stent Implantation, DAPT(Dual Antiplatelet Therapy)
- Trial name
- DIOHR (NCT07140133)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Grenoble
Angioplasty, Transluminal, Percutaneous Coronary
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two…
- Trial name
- NCT00269880
- Testing
- Heparin, Abciximab
- Volunteers
- 2,792 people
- Sponsor
- Centocor, Inc.
Coronary Artery Disease
(EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))
The purpose of this study is to test the impact of a multidisciplinary approach to improve the adhesion and persistence to Clopidogrel therapy.
- Trial name
- EASY-IMPACT (NCT01134679)
- Testing
- Multi-disciplinary disease management approach
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Laval University
Hemorrhage Brain
Delayed Intracranial Hemorrhages in Patients With Minor Head Injury on Anticoagulant or Dual Anti-platelet Therapy
Retrospective observational study on a cohort of 2 years to evaluate the incidence of brain hemorrhage present at control head CT scan executed after routine 24h observation period of ED stay in patients with minor head injury on…
- Trial name
- NCT07631936
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS San Raffaele
Anti Platelet Effects
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12…
- Trial name
- DOSAPI (NCT01175200)
- Testing
- Clopidogrel, Prasugrel, Lansoprazole
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Ascopharm Groupe Novasco
Antiplatelet Therapy of Coronary Artery Bypass
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting
This study is designed to demonstrate that the onset of the antiplatelet effect of 90mg bid dose ticagrelor is more rapid and greater than 75 mg qd dose clopidogrel in patients undergoing CABG surgery.
- Trial name
- ATCCC (NCT02330640)
- Testing
- ticagrelor, clopidogrel, asprin
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study
To prospectively evaluate in a multicenter open label trial whether the use of zotarolimus-eluting ENDEAVOR Stent implantation in patients at low restenosis or at high bleeding or thrombotic risk will decrease the incidence of…
- Trial name
- ZEUS (NCT01385319)
- Testing
- Bare metal stent implantation, zotarolimus eluting stent
- Where
- 16 sites in Hungary, Italy and 2 more
- Volunteers
- 1,606 people
- Sponsor
- Marco Valgimigli
Acute Coronary Syndrome, Coronary Artery Disease
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy.
- Trial name
- NCT03252249
- Testing
- 3 months dual anti-platelet therapy, 12 months dual anti-platelet therapy
- Where
- United Kingdom
- Volunteers
- 5,094 people
- Sponsor
- University of Edinburgh
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation, Acute Coronary Syndrome
Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation
Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated and fast atrial activity, and coronary artery disease (chronic and acute coronary syndrome) is characterized by a generally atheromatous…
- Conditions
- Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis, Hemorrhage
- Trial name
- FACOREV (NCT05068414)
- Testing
- Blood panel
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes